[O-33] Oral Session 33
Neuroimaging・Clinical trial　etc

[O-33-4] FIREFISH Part 2: Efficacy and safety of risdiplam in infants with Type 1 spinal muscular atrophy

^○Yasuhiro Takeshima¹, Laurent Servais², Giovanni Baranello³, Maria Mazurkiewicz-beldzinska⁴, Kristy Rose⁵, Dmitry Vlodavets⁶, Hui Xiong⁷, Muna El-khairi⁸, Sabine Fuerst-recktenwald⁸, Marianne Gerber⁸, Ksenija Gorni⁸, Heidemarie Kletzl⁸, Renata Scalco⁸, Tomoko Yagishita⁹, Basil T. Darras¹⁰ (1.Department of Pediatrics, Hyogo College of Medicine, 2.Reference Center for Neuromuscular Disease, Centre Hospitalier Régional de La Citadelle, 3.Carlo Besta Neurological Research Institute Foundation, Developmental Neurology Unit, 4.Department of Developmental Neurology, Medical University of Gdansk, 5.Paediatric Gait Analysis Service of New South Wales, The Children's Hospital at Westmead Sydney, 6.Russian Children Neuromuscular Center, Veltischev Clinical Pediatric Research Institute of Pirogov Russian National Research Medical University, 7.Department of Pediatrics, Peking University First Hospital, 8.F. Hoffmann-La Roche Ltd., 9.Chugai Pharmaceutical Co., Ltd., 10.Boston Children's Hospital, Harvard Medical School)